Predictions
Reata Pharmaceuticals Inc
Start price
Target price
Perf. (%)
€25.40
28.03.22
28.03.22
-
28.03.23
28.03.23
25.20%
02.04.22
02.04.22
Risky Investment
Riot Blockchain Inc.
Start price
Target price
Perf. (%)
€21.16
28.03.22
28.03.22
-
28.03.23
28.03.23
-9.86%
02.04.22
02.04.22
Risky Investment
Bristol-Myers Squibb
Start price
Target price
Perf. (%)
€66.35
25.03.22
25.03.22
-
25.04.22
25.04.22
6.07%
26.04.22
26.04.22
Could be very worthwhile Investment >20% year
Revenue growth >5% per year expected
High dividend yield expected
Good rating
Pfizer Inc.
Start price
Target price
Perf. (%)
€47.88
25.03.22
25.03.22
€64.00
25.03.23
25.03.23
-21.14%
27.03.23
27.03.23
Could be worthwhile Investment >10% per year
Kineta Inc.
Start price
Target price
Perf. (%)
€12.46
24.03.22
24.03.22
-
24.03.23
24.03.23
-23.03%
02.04.22
02.04.22
Probably not worthwhile Investment
Pfizer Inc.
Start price
Target price
Perf. (%)
€48.26
23.03.22
23.03.22
€55.00
23.03.23
23.03.23
-3.61%
02.04.22
02.04.22
Could be worthwhile Investment >10% per year
Top 10 in its market
Known brand
Small cyclical dependencies
Palisade Bio Inc.
Start price
Target price
Perf. (%)
€59.50
22.03.22
22.03.22
-
22.03.23
22.03.23
-20.59%
31.03.22
31.03.22
Risky Investment
Pacira Pharmaceuticals
Start price
Target price
Perf. (%)
€64.50
22.03.22
22.03.22
-
22.03.23
22.03.23
-43.57%
23.03.23
23.03.23
Voyager Therapeutics Inc
Start price
Target price
Perf. (%)
€7.65
21.03.22
21.03.22
€11.00
21.03.23
21.03.23
-7.01%
22.03.23
22.03.23
Could be worthwhile Investment >10% per year
Higher risks for its business
PAVmed Inc
Start price
Target price
Perf. (%)
€1.35
21.03.22
21.03.22
€8.00
21.03.23
21.03.23
-14.92%
02.04.22
02.04.22
Could be worthwhile Investment >10% per year
EBIT growth >5% per year expected
Higher EBIT margin than peer group
Revenue decline/stagnation expected
Lipocine Inc.
Start price
Target price
Perf. (%)
€25.25
21.03.22
21.03.22
€0.000
21.03.23
21.03.23
-19.90%
02.04.22
02.04.22
Below average Management
high free float
High risks for its business
Unknown brand
PAVmed Inc
Start price
Target price
Perf. (%)
€1.41
20.03.22
20.03.22
-
20.03.23
20.03.23
-80.13%
21.03.23
21.03.23
Probably not worthwhile Investment
Bovie Medical Corp
Start price
Target price
Perf. (%)
€6.45
20.03.22
20.03.22
-
20.03.23
20.03.23
-8.53%
28.05.22
28.05.22
Risky Investment
Novocure Ltd
Start price
Target price
Perf. (%)
€64.20
16.03.22
16.03.22
€68.00
16.03.23
16.03.23
-6.99%
17.03.23
17.03.23
Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
Teladoc Health Inc
Start price
Target price
Perf. (%)
€54.20
16.03.22
16.03.22
€65.00
16.03.23
16.03.23
-43.24%
28.04.22
28.04.22
Significant cyclical dependencies
ROE lower than 10% per year
high free float
Little known brand
Chemocentryx Inc.
Start price
Target price
Perf. (%)
€21.29
16.03.22
16.03.22
€56.00
16.03.23
16.03.23
149.27%
17.03.23
17.03.23
Lower EBIT Margin than peer group
Very low/no dividend yield expected
negative Cash Flow expected
Bad rating
Kala Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€81.03
15.03.22
15.03.22
-
15.03.23
15.03.23
-14.84%
20.03.22
20.03.22
Could be worthwhile Investment >10% per year
Chemocentryx Inc.
Start price
Target price
Perf. (%)
€20.53
14.03.22
14.03.22
€14.00
14.03.23
14.03.23
3.70%
16.03.22
16.03.22
Lower EBIT Margin than peer group
Very low/no dividend yield expected
negative Cash Flow expected
Bad rating
Teladoc Health Inc
Start price
Target price
Perf. (%)
€46.58
14.03.22
14.03.22
€35.00
14.03.23
14.03.23
16.36%
16.03.22
16.03.22
Significant cyclical dependencies
ROE lower than 10% per year
high free float
Little known brand
Minerva Neurosciences Inc.
Start price
Target price
Perf. (%)
€4.81
14.03.22
14.03.22
€6.40
14.03.23
14.03.23
-33.68%
11.06.22
11.06.22
Standard Investments for future growth
Higher EBIT margin than peer group
Very low/no dividend yield expected
ROE lower than 10% per year
Eurobio scientific
Start price
Target price
Perf. (%)
€19.28
14.03.22
14.03.22
€21.00
14.03.23
14.03.23
-10.58%
05.10.22
05.10.22
Could be worthwhile Investment >10% per year